Santin AD - Search Results

1

HER2/neu in Endometrial Cancer: A Promising Therapeutic Target With Diagnostic Challenges.

Buza N, Roque DM, Santin AD. Buza N, et al. Among authors: santin ad. Arch Pathol Lab Med. 2014 Mar;138(3):343-50. doi: 10.5858/arpa.2012-0416-RA. Arch Pathol Lab Med. 2014. PMID: 24576030 Free article. Review.

2

Overexpression of HER-2/neu in uterine serous papillary cancer.

Santin AD, Bellone S, Gokden M, Palmieri M, Dunn D, Agha J, Roman JJ, Hutchins L, Pecorelli S, O'Brien T, Cannon MJ, Parham GP. Santin AD, et al. Clin Cancer Res. 2002 May;8(5):1271-9. Clin Cancer Res. 2002. PMID: 12006548

3

Selection of HER-2/neu-positive tumor cells in early stage cervical cancer: implications for Herceptin-mediated therapy.

Bellone S, Palmieri M, Gokden M, Joshua J, Roman JJ, Pecorelli S, Cannon MJ, Santin AD. Bellone S, et al. Among authors: santin ad. Gynecol Oncol. 2003 Oct;91(1):231-40. doi: 10.1016/s0090-8258(03)00460-8. Gynecol Oncol. 2003. PMID: 14529687

4

Current treatment options for endometrial cancer.

Santin AD, Bellone S, O'Brien TJ, Pecorelli S, Cannon MJ, Roman JJ. Santin AD, et al. Expert Rev Anticancer Ther. 2004 Aug;4(4):679-89. doi: 10.1586/14737140.4.4.679. Expert Rev Anticancer Ther. 2004. PMID: 15270671 Review.

5

Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer.

Santin AD, Bellone S, Siegel ER, Palmieri M, Thomas M, Cannon MJ, Kay HH, Roman JJ, Burnett A, Pecorelli S. Santin AD, et al. Am J Obstet Gynecol. 2005 Mar;192(3):813-8. doi: 10.1016/j.ajog.2004.10.605. Am J Obstet Gynecol. 2005. PMID: 15746676

6

Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization.

Santin AD, Bellone S, Van Stedum S, Bushen W, De Las Casas LE, Korourian S, Tian E, Roman JJ, Burnett A, Pecorelli S. Santin AD, et al. Gynecol Oncol. 2005 Jul;98(1):24-30. doi: 10.1016/j.ygyno.2005.03.041. Gynecol Oncol. 2005. PMID: 15894362

7

High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer.

Bellone S, Watts K, Cane' S, Palmieri M, Cannon MJ, Burnett A, Roman JJ, Pecorelli S, Santin AD. Bellone S, et al. Among authors: santin ad. Gynecol Oncol. 2005 Jul;98(1):92-8. doi: 10.1016/j.ygyno.2005.03.016. Gynecol Oncol. 2005. PMID: 15904949 Free article.

8

Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu.

Santin AD, Bellone S, Roman JJ, McKenney JK, Pecorelli S. Santin AD, et al. Int J Gynaecol Obstet. 2008 Aug;102(2):128-31. doi: 10.1016/j.ijgo.2008.04.008. Epub 2008 Jun 16. Int J Gynaecol Obstet. 2008. PMID: 18555254

9

Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy.

Bellone S, Siegel ER, Cocco E, Cargnelutti M, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Bellone S, et al. Among authors: santin ad. Int J Gynecol Cancer. 2009 Jul;19(5):860-6. doi: 10.1111/IGC.0b013e3181a8331f. Int J Gynecol Cancer. 2009. PMID: 19574774

10

Serum amyloid A: a novel biomarker for endometrial cancer.

Cocco E, Bellone S, El-Sahwi K, Cargnelutti M, Buza N, Tavassoli FA, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Cocco E, et al. Among authors: santin ad. Cancer. 2010 Feb 15;116(4):843-51. doi: 10.1002/cncr.24838. Cancer. 2010. PMID: 20041483 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

318 results

Search Page